Group leader
Prof. Reiner Jumpertz-Von Schwartzenberg
Fields of Work and Expertise
Endocrinological diseases Obesity Diabetes mellitus Metabolic diseases
- Translational obesity and diabetes research
- Regulation of food absorption in humans
- Interaction intestinal microbiome and metabolism
Professional Background
Prof. Dr. Reiner Jumpertz-von Schwartzenberg has been appointed as Full Professor for Clinical Metabolism and Obesity Research at the Medical Faculty of the University of Tübingen in conjunction with the Helmholtz Center Munich since May 2022.
He studied medicine in Bochum and Leipzig where he obtained his doctorate in 2012. Between 2011 and 2021 he has completed his clinical training at the Charité in Berlin and became a board-certified internist, endocrinologist and diabetologist. He became member of the first clinician scientist program in Germany focussing on the interaction of diets, metabolism and the gut microbiome.
During his stays abroad as a visiting scientist at the National Institute of Health (NIH) in the USA and the University of California/San Francisco, Prof. Dr. Reiner Jumpertz-von Schwartzenberg gained a deep understanding in clinical trial design in human metabolism research and basic translational microbiome science.
Since 2021, Prof. Dr. Jumpertz-von Schwartzenberg serves as a senior physician for the Department of Diabetology, Endocrinology, and Nephrology, and is the head of the clinical study center at the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University Hospital Tübingen. Additionally, he leads a Helmholtz Young Investigator Group and is a Junior Research Group leader in the Cluster of Excellence Controlling Microbes to Fight Infections (CMFI) in Tübingen.
His research focuses on understanding the mechanisms underlying the development, treatment and remission of metabolic diseases, with a specific emphasis on exploring the interactions between the gut microbiome and host metabolism.
Reiner Jumpertz-von Schwartzenberg as a guest at "Habitat Mensch"
What can be done to build a healthy gut microbiome with the help of diets?
Note on advertising in videos
WEBSITE-URL has no influence on advertising content that is displayed before, during or after WEBSITE-URL videos. We assume no liability for this content. Further information can be found here.
DOC Fischer 22.11.2023
Prediabetes - what's behind it and does a lifestyle change help?
DOC Fischer 27.10.2021
Sweeteners - how dangerous are they?
Medical Tribune
Tailor-made therapies as a research objective
How a low-calorie diet changes the gut microbiome
Innovations Report
Publications
Wang, Y. ; Sandforth, A. ; Jumpertz von Schwartzenberg, R. ; Ganslmeier, M. ; Cheng, Y. ; Sandforth, L. ; Katzenstein, S. ; Machann, J. ; Schick, F. ; Kantartzis, K. ; Preissl, H. ; Fritsche, A. ; Stefan, N. ; Bergman, M. ; Birkenfeld, A.L.
Lifestyle intervention is more effective in high 1-hour post-load glucose than in prediabetes for restoring β-cell function, reducing ectopic fat, and preventing type 2 diabetes.Gehmeyr, M. ; Rojas López, M.B. ; Nitkunanantharajah, S. ; Preissl, H. ; Vosseler, A. ; Jumpertz von Schwartzenberg, R. ; Birkenfeld, A.L. ; Katsouli, N. ; Fasoula, N. ; Karlas, A. ; Kallmayer, M. ; Ziegler, A.-G. ; Jüstel, D. ; Ntziachristos, V.
Enhanced maximum intensity projection (eMIP) for improving the fidelity of optoacoustic images.Sandforth, A. ; Arreola, E.V. ; Hanson, R.L. ; Wewer Albrechtsen, N.J. ; Holst, J.J. ; Ahrends, R. ; Coman, C. ; Gerst, F. ; Lorza-Gil, E. ; Cheng, Y. ; Sandforth, L. ; Katzenstein, S. ; Ganslmeier, M. ; Seissler, J. ; Hauner, H. ; Perakakis, N. ; Wagner, R. ; Machann, J. ; Schick, F. ; Peter, A. ; Lehmann, R. ; Weigert, C. ; Maurer, J. ; Preissl, H. ; Heni, M. ; Szendrödi, J. ; Kopf, S. ; Solimena, M. ; Schwarz, P. ; Blüher, M. ; Häring, H.-U. ; Hrabě de Angelis, M. ; Schürmann, A. ; Kabisch, S. ; Mai, K. ; Pfeiffer, A.F.H. ; Bornstein, S. ; Stumvoll, M. ; Roden, M. ; Stefan, N. ; Fritsche, A. ; Birkenfeld, A.L. ; Jumpertz von Schwartzenberg, R.
Prevention of type 2 diabetes through prediabetes remission without weight loss.Sandforth, L. ; Raverdy, V. ; Sandforth, A. ; Bauvin, P. ; Chatelain, E. ; Verkindt, H. ; Mingrone, G. ; Guidone, C. ; Verrastro, O. ; Zhou, K. ; Archid, R. ; Mihaljevic, A.L. ; Caiazzo, R. ; Baud, G. ; Marciniak, C. ; Chetboun, M. ; Ganslmeier, M. ; Minelli Faiao, V. ; Heni, M. ; Fritsche, L. ; Moller, A. ; Kantartzis, K. ; Peter, A. ; Lehmann, R. ; Wagner, R. ; Prystupa, K. ; Fritsche, A. ; Stefan, N. ; Preissl, H. ; Birkenfeld, A.L. ; Jumpertz von Schwartzenberg, R. ; Pattou, F.
Subphenotype-dependent benefits of bariatric surgery for individuals at risk for type 2 diabetes.Schork, A. ; Fritsche, A. ; Schleicher, E.D. ; Peter, A. ; Heni, M. ; Stefan, N. ; Jumpertz von Schwartzenberg, R. ; Guthoff, M. ; Mischak, H. ; Siwy, J. ; Birkenfeld, A.L. ; Wagner, R.
Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics.Sandforth, L. ; Kullmann, S. ; Sandforth, A. ; Fritsche, A. ; Jumpertz von Schwartzenberg, R. ; Stefan, N. ; Birkenfeld, A.L.
Prediabetes remission to reduce the global burden of type 2 diabetes.Barovic, M. ; Hahn, J.J. ; Heinrich, A. ; Adhikari, T. ; Schwarz, P.E. ; Mirtschink, P. ; Funk, A. ; Kabisch, S. ; Pfeiffer, A.F.H. ; Blüher, M. ; Seissler, J. ; Stefan, N. ; Wagner, R. ; Fritsche, A. ; Jumpertz von Schwartzenberg, R. ; Chlamydas, S. ; Harb, H. ; Mantzoros, C.S. ; Chavakis, T. ; Schürmann, A. ; Birkenfeld, A.L. ; Roden, M. ; Solimena, M. ; Bornstein, S.R. ; Perakakis, N.
Proteomic and metabolomic signatures in prediabetes progressing to diabetes or reversing to normoglycemia within 1 Year.Eisinger, F. ; Neumann, M. ; Wörn, M. ; Fritsche, A. ; Heyne, N. ; Peter, A. ; Birkenfeld, A.L. ; Jumpertz von Schwartzenberg, R. ; Artunc, F.
Comparison of GFR estimation in patients with diabetes mellitus using the EKFC and CKD-EPI equations.Lorza-Gil, E. ; Strauss, O. ; Ziegler, E. ; Kansy, K. ; Katschke, M.-T. ; Rahimi, G. ; Neuscheler, D. ; Sandforth, L. ; Sandforth, A. ; Sancar, G. ; Kaufmann, B. ; Hartmann, D. ; Singer, S.R. ; Mihaljevic, A.L. ; Jumpertz von Schwartzenberg, R. ; Sbierski-Kind, J. ; Müller, T.D. ; Birkenfeld, A.L. ; Gerst, F.
Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research.Wagner, R. ; Buettner, J. ; Heni, M. ; Fritsche, L. ; Kullmann, S. ; Wagmüller, M. ; Peter, A. ; Preissl, H. ; Machann, J. ; Jumpertz von Schwartzenberg, R. ; Birkenfeld, A.L. ; Pape, U.F. ; van Hall, G. ; Plomgaard, P. ; Häring, H.-U. ; Fritsche, A. ; Thompson, K.N. ; Klein, R. ; Stefan, N.
Carrageenan and insulin resistance in humans: A randomised double-blind cross-over trial.
German Center for Diabetes Research
